The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 299.00
Bid: 296.00
Ask: 298.00
Change: -3.00 (-0.99%)
Spread: 2.00 (0.676%)
Open: 300.00
High: 304.00
Low: 296.00
Prev. Close: 302.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-Close Trading Update and Board Update

14 Jan 2021 07:00

RNS Number : 6235L
Synthomer PLC
14 January 2021
 

14th January 2021

 

Synthomer plc

 

Pre-Close Trading Update and Board Update

 

FY2020 EBITDA guidance raised c.10%; FY2020 proforma leverage expected to reduce further

Calum MacLean to stand down as Chief Executive by January 2022

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the year ended 31st December 2020 ahead of announcing the Group's Full Year results on 4th March 2021. Synthomer also announces that following 6 successful years, Calum MacLean has informed the Board that he intends to stand down as Chief Executive by January 2022.

 

Strong trading momentum across the business

 

Performance Elastomers

 

Performance Elastomers has continued to perform strongly. The positive trends experienced in our Nitrile latex business during the year continued through the final quarter of 2020 with overall performance ahead of expectations. Similarly, the conditions in our SBR latex business also continued to strengthen, with all SBR segments except paper trading ahead of the comparative period in 2019.

 

Functional Solutions

 

Functional Solutions has seen a sustained improvement in the final quarter of 2020 with our consumer facing and industrial end markets remaining strong with exception of the Oil and Gas business unit. We have seen activity levels above normal seasonal levels with overall performance ahead of expectations.

 

Industrial Specialities

 

Industrial Specialities also had a strong finish to the year, with our laminates and films business, which serves the home improvement and recreational vehicles market, trading particularly well and the division performing ahead of the equivalent period in 2019. 

 

FY 2020 EBITDA guidance raised and proforma leverage expected to reduce further

 

The combination of stronger trading across our three major divisions means that the Group now expects its 2020 EBITDA to be approximately £255m, some 10% ahead of the Company guidance of £232m provided in our trading statement of 14th October 2020.

 

The Group remains highly cash generative and now expects proforma leverage to reduce to circa 1.9x net debt to EBITDA as of 31st December 2020.

 

Outlook

 

Whilst the Group will continue to adapt its operations in response to the ongoing COVID-19 pandemic to ensure the safety of all employees, at this stage it expects no meaningful disruption to business. The Board is confident that the benefits of the OMNOVA acquisition, recent investment in new capacity, further efficiency measures, its proven growth strategy as well as continued strength in Performance Elastomers, will underpin strong EBITDA growth in 2021.

 

Board update

 

Having informed the Board that he would like to stand down as Chief Executive, Calum MacLean will leave the business by January 2022 when a successor is in place. During his 6 years as Chief Executive, Calum has driven significant change at Synthomer presiding over substantial investment and several acquisitions, notably Omnova in 2020. The process to find a new Chief Executive is underway and is expected to include both internal and external candidates. A further announcement will be made in due course.

 

Commenting Calum MacLean, Chief Executive, said:

 

"It has been a privilege to lead Synthomer for the last 6 years and I am proud of what we have achieved. With Omnova fully integrated, all core parts of the business growing and our financial outlook strong, now is the right time to hand over to someone else who can build on this exciting momentum. I look forward to welcoming my successor into the role when the time comes."

 

Commenting, Caroline Johnstone, Chair of Synthomer, said:

 

"In a very challenging year, Synthomer has delivered a strong performance, testament to the strategy that we have been consistently executing and the investments that we have made over the last five years. As we embark upon a new year and look further ahead to the future, the business is in a strong position.On behalf of the Board, I would like to thank Calum for everything that he has done to take Synthomer forward since joining at the start of 2015. His leadership and vision have transformed the business into a truly diversified, differentiated and global company. The next chapter promises to be just as exciting and the Board looks forward to working with a new Chief Executive in due course."

 

-ENDS-

 

Further information:

 

Calum MacLean, Chief Executive Officer

Steve Bennett, Chief Financial Officer Tel: + 44 1279 436211

Tim Hughes, President, Corporate Development

 

Charles Armitstead/ Matt Denham, Teneo Tel: + 44 7703 330 269/ + 44 7825 735596

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFIILIIVLIL
Date   Source Headline
30th Jul 20197:00 amRNSResults of Rights Issue
26th Jul 20192:48 pmRNSDirector/PDMR Shareholding
26th Jul 20192:46 pmRNSDirector/PDMR Shareholding
24th Jul 20194:34 pmRNSDirector Declaration
15th Jul 20197:00 amRNSAdmission of Nil Paid Rights
10th Jul 20191:49 pmRNSPublication of Circular and Prospectus
10th Jul 20191:34 pmRNSDirector/PDMR Shareholding
3rd Jul 20197:00 amRNSAcquisition
2nd Jul 20193:56 pmRNSDirector Declaration
13th Jun 201911:18 amRNSDirector Declaration
25th Apr 20194:45 pmRNSResult of AGM
25th Apr 20197:00 amRNSQ1 Trading Update
10th Apr 20194:51 pmRNSDirector/PDMR Shareholding
10th Apr 20194:50 pmRNSDirector/PDMR Shareholding
10th Apr 20194:43 pmRNSDirector/PDMR Shareholding
10th Apr 20194:41 pmRNSDirector/PDMR Shareholding
28th Mar 20193:51 pmRNSDirector/PDMR Shareholding
28th Mar 20193:50 pmRNSDirector/PDMR Shareholding
25th Mar 20193:15 pmRNSAnnual Financial Report
21st Mar 20193:39 pmRNSDirector Declaration
18th Mar 201910:02 amRNSDirector/PDMR Shareholding
12th Mar 201911:25 amRNSDirector/PDMR Shareholding
12th Mar 201911:23 amRNSDirector/PDMR Shareholding
5th Mar 20194:09 pmRNSDirector/PDMR Shareholding
4th Mar 20197:00 amRNSResults for the year ended 31 December 2018
1st Mar 20193:26 pmRNSDirector Declaration
3rd Dec 201810:54 amRNSHolding(s) in Company
9th Nov 201811:36 amRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSQ3 Trading update
17th Oct 20189:29 amRNSDirector Declaration
21st Sep 20189:17 amRNSDirectorate Change
6th Aug 20187:00 amRNSResults for the six months ended 30 June 2018
11th Jul 20186:25 pmRNSDirector/PDMR Shareholding
10th Jul 20189:47 amRNSHolding(s) in Company
4th Jul 201811:45 amRNSHolding(s) in Company
4th Jul 201811:44 amRNSHolding(s) in Company
4th Jul 201811:43 amRNSHolding(s) in Company
28th Jun 20183:12 pmRNSUpdate on Proposed Offering
25th Jun 20187:19 amRNSPROPOSED OFFERING OF EUR300M BOND & REFINANCING
21st Jun 201810:16 amRNSResult of Extraordinary General Meeting
8th Jun 20187:00 amRNSEuropean Commission investigation
4th Jun 20181:02 pmRNSNotice of GM
3rd May 20181:38 pmRNSHolding(s) in Company
2nd May 20184:29 pmRNSDirector/PDMR Shareholding
26th Apr 20182:23 pmRNSResult of AGM
26th Apr 20187:00 amRNSQ1 Trading update
9th Apr 20184:54 pmRNSDirector Declaration
27th Mar 20181:03 pmRNSDirector/PDMR Shareholding
27th Mar 20181:01 pmRNSDirector/PDMR Shareholding
26th Mar 20184:55 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.